94 related articles for article (PubMed ID: 33316417)
1. First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings.
Ferro M; Lucarelli G; Crocetto F; Dolce P; Verde A; La Civita E; Zappavigna S; de Cobelli O; Di Lorenzo G; Facchini BA; Scafuri L; Onofrio L; Porreca A; Busetto GM; Sonpavde G; Caraglia M; Klain M; Terracciano D; De Placido S; Buonerba C
Crit Rev Oncol Hematol; 2021 Jan; 157():103198. PubMed ID: 33316417
[TBL] [Abstract][Full Text] [Related]
2. Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.
Grisay G; Lavaud P; Fizazi K
Curr Oncol Rep; 2024 May; 26(5):488-495. PubMed ID: 38592590
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration.
Freedland SJ; Sandin R; Sah J; Emir B; Mu Q; Ratiu A; Hong A; Serfass L; Tagawa ST
Cancer Med; 2021 Dec; 10(23):8570-8580. PubMed ID: 34725947
[TBL] [Abstract][Full Text] [Related]
4. Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer.
Briones J; Khan M; Sidhu AK; Zhang L; Smoragiewicz M; Emmenegger U
Front Oncol; 2021; 11():658331. PubMed ID: 34026638
[TBL] [Abstract][Full Text] [Related]
5. WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?
Omrčen T
Acta Clin Croat; 2019 Nov; 58(Suppl 2):69-72. PubMed ID: 34975201
[TBL] [Abstract][Full Text] [Related]
6. Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor.
Watanabe H; Nakane K; Takahara K; Naiki T; Yasui T; Shiroki R; Koie T; Miyake H
Int J Urol; 2024 May; ():. PubMed ID: 38764245
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.
Sutera P; Shetty AC; Song Y; Hodges T; Hoang T; Rana Z; Pienta K; Feng F; Song DY; DeWeese T; Gillessen S; Sweeney C; James N; Attard G; Deek M; Tran PT
Eur Urol Oncol; 2024 Apr; 7(2):241-247. PubMed ID: 37558543
[TBL] [Abstract][Full Text] [Related]
8. Highlighting recent progress in the treatment of men with advanced prostate cancer.
Gourdin T
Curr Opin Oncol; 2024 May; 36(3):174-179. PubMed ID: 38573207
[TBL] [Abstract][Full Text] [Related]
9. Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial.
Fukuokaya W; Yanagisawa T; Mori K; Urabe F; Rajwa P; Briganti A; Shariat SF; Kimura T
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38688767
[TBL] [Abstract][Full Text] [Related]
10. Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.
George DJ; Agarwal N; Ramaswamy K; Klaassen Z; Bitting RL; Russell D; Sandin R; Emir B; Yang H; Song W; Lin Y; Hong A; Gao W; Freedland SJ
Prostate Cancer Prostatic Dis; 2024 Apr; ():. PubMed ID: 38565911
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
Zhou S; Alerasool P; Kishi N; Joshi H; Sahni G; Tsao CK
Clin Genitourin Cancer; 2024 Jun; 22(3):102066. PubMed ID: 38584004
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Treatment for Metastatic Hormone-Sensitive Prostate Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses.
Sirisreetreerux P; Poprom N; Numthavaj P; Rattanasiri S; Thakkinstian A
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136260
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Nutritional Index (PNI): A New Biomarker for Determining Prognosis in Metastatic Castration-Sensitive Prostate Carcinoma.
Ellez HI; Keskinkilic M; Semiz HS; Arayici ME; Kısa E; Oztop I
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685501
[TBL] [Abstract][Full Text] [Related]
14. Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.
Kafka M; Burtscher T; Fritz J; Schmitz M; Bektic J; Ladurner M; Horninger W; Heidegger I
World J Urol; 2023 Aug; 41(8):2043-2050. PubMed ID: 36287244
[TBL] [Abstract][Full Text] [Related]
15. Advancements in the treatment of metastatic hormone-sensitive prostate cancer.
Li H; Zhang M; Wang X; Liu Y; Li X
Front Oncol; 2022; 12():913438. PubMed ID: 36059610
[TBL] [Abstract][Full Text] [Related]
16. The Role of Curcumin in Prostate Cancer Cells and Derived Spheroids.
Boccellino M; Ambrosio P; Ballini A; De Vito D; Scacco S; Cantore S; Feola A; Di Donato M; Quagliuolo L; Sciarra A; Galasso G; Crocetto F; Imbimbo C; Boffo S; Di Zazzo E; Di Domenico M
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884410
[TBL] [Abstract][Full Text] [Related]
17. Where Do We Stand in the Management of Oligometastatic Prostate Cancer? A Comprehensive Review.
Juan GR; Laura FH; Javier PV; Natalia VC; Mᵃ Isabel GR; Enrique RG; José Luis SP; Pablo AL; Noelia SS; Roser VD; Jesús MS
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454924
[TBL] [Abstract][Full Text] [Related]
18. Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review.
Loizzo D; Pandolfo SD; Rogers D; Cerrato C; di Meo NA; Autorino R; Mirone V; Ferro M; Porta C; Stella A; Bizzoca C; Vincenti L; Spilotros M; Rutigliano M; Battaglia M; Ditonno P; Lucarelli G
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409187
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?
von Amsberg G; Alsdorf W; Karagiannis P; Coym A; Kaune M; Werner S; Graefen M; Bokemeyer C; Merkens L; Dyshlovoy SA
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269712
[TBL] [Abstract][Full Text] [Related]
20. Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy.
Lorenzo GD; Scafuri L; Costabile F; Pepe L; Scognamiglio A; Crocetto F; Guerra G; Buonerba C
Future Sci OA; 2022 Mar; 8(3):FSO784. PubMed ID: 35251698
[No Abstract] [Full Text] [Related]
[Next] [New Search]
